Holen Sie sich die Stockscreener-App
131.00
1.54%
-2.15
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock - ChartMill
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - Sahm
Momentum Shift: What hedge funds are buying Neurocrine Biosciences IncMarket Activity Recap & Verified Technical Trade Signals - baoquankhu1.vn
Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple - Yahoo Finance
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - The Economic Times
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $176 - Moomoo
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $242 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology - The Chronicle-Journal
Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush - MarketBeat
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox
Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to acquire Soleno in $2.9bn transaction - Pharmaceutical Technology
Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition By Investing.com - Investing.com India
TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition - Investing.com
Neurocrine to acquire Soleno in multi-billion dollar deal - marketscreener.com
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - Bitget
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - Yahoo Finance
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²
Neurocrine to seek Soleno (NASDAQ: SLNO) shares via tender offer - Stock Titan
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - axios.com
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - MedCity News
Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals
Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan
Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com - Investing.com India
Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - WHTC
Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView
Oppenheimer raises Neurocrine Biosciences price target on acquisition By Investing.com - Investing.com Canada
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily
Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com
Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Neurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease Portfolio - Pulse 2.0
Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - MarketBeat
Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? - BioWorld News
Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1 - Minichart
UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com - Investing.com South Africa
Optimal Consolidation: Soleno Acquired by Neurocrine - Gotrade
Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen - Stocktwits
UBS reiterates Neurocrine Bio stock rating on acquisition news - Investing.com
3.43%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):